New Analysis of 25 Million Pregnancies Finds No Link Between Antidepressants and Autism or ADHD Risk

May 15, 2026 — A landmark analysis involving more than 25 million pregnancies has found no causal link between the use of antidepressants during pregnancy and an increased risk of autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) in children. The study, published May 14, 2026, in The Lancet Psychiatry, provides critical reassurance to millions of expectant mothers and healthcare providers navigating the complexities of prenatal mental health.

Led by researchers at the University of Hong Kong, the comprehensive study analyzed data from nearly 650,000 pregnancies where antidepressants were used, comparing them against 25 million pregnancies without medication exposure. The findings strongly suggest that earlier research—which pointed toward a potential risk—likely misidentified the medication as the cause, when the true drivers were underlying genetic and familial factors.

Key Findings: Disentangling Medication from Genetics

The study’s initial raw data appeared to support older concerns, showing a 35% higher risk of ADHD and a 69% higher risk of autism in children exposed to antidepressants in utero. However, this association vanished once researchers applied rigorous controls for “confounding variables.”

By accounting for the mother’s pre-existing mental health history, genetic predispositions, and family environment, the researchers found that the risks became statistically insignificant. The most compelling evidence for this shift came from “sibling” and “paternal” comparisons:

• Paternal Influence: Children whose fathers took antidepressants around the time of conception showed similar increased risks for ASD and ADHD, even though the fetus was never biologically exposed to the drug.

• Pre-Pregnancy Use: Mothers who used antidepressants before pregnancy, but stopped before conception, had children with similar risk profiles to those who continued medication.

• Class Consistency: The lack of a causal link remained consistent across various classes of antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).

“These patterns suggest that antidepressants are not the direct cause of neurodevelopmental disorders,” the research team noted. Instead, the genetic susceptibility to depression and ADHD—traits that often co-occur within families—appears to be the primary factor.

Why Previous Research Diverged

The discrepancy between this landmark study and previous smaller studies often comes down to a phenomenon known as confounding by indication. This occurs when the condition being treated (depression) is itself linked to the outcome being studied (neurodevelopmental changes), making it difficult to tell if the “cure” or the “cause” is responsible.

Dr. Roy Perlis, an associate professor of psychiatry at Harvard Medical School and Massachusetts General Hospital, has long studied this intersection. “When you don’t account for the mother’s depression severity and genetic factors, it looks like the medication is causing the problem,” Dr. Perlis explained. “But once you control for these factors, the association disappears.”

Early observational studies often lacked the massive datasets required to tease apart these nuances, leading to years of “medical “fear-mongering” that left many pregnant women in an agonizing position: choose their own mental stability or their child’s developmental health.

Expert Commentary: Relieving the Burden of Guilt

For maternal health experts, the findings are a powerful tool for patient education. Carmine Pariante, a professor of Biological Psychiatry at King’s College London, noted in an independent commentary that the study effectively clears the medication’s name.

“What this study shows is that previous concerns… are due to the effects of depression itself, or to risk factors for depression, and not to antidepressants,” Pariante said.

Dr. Chi-Chung, the study’s principal investigator at the University of Hong Kong, emphasized the human element of the data. “We understand that many expectant parents are concerned about the effects of medications. Our findings offer reassuring evidence that commonly prescribed antidepressants do not heighten these specific risks.”

The Danger of Untreated Depression

While the fear of medication side effects is a common driver of clinical decisions, experts warn that the risks of untreated depression are far more documented and dangerous. According to the Society for Maternal-Fetal Medicine (SMFM), discontinuing antidepressants during pregnancy frequently leads to a relapse of major depressive disorder.

Untreated maternal depression is linked to:

• Physical Complications: Higher rates of preeclampsia, preterm birth, and low birth weight.

• Psychological Risks: Increased risk of suicidal ideation and severe postpartum depression.

• Developmental Impacts: Challenges in maternal-infant bonding and increased stress hormones that can affect the developing fetus.

“The key takeaway is simple,” said Walker, a maternal health expert involved in the study’s broader discourse. “Women suffering from moderate or severe depression should not discontinue their antidepressants due to fears of causing autism. Untreated depression poses significant risks to the mother and the developing child.”

Study Limitations

Despite the scale of the analysis, researchers noted a few caveats. As an observational study rather than a randomized controlled trial (which would be unethical in pregnant populations), researchers relied on existing health records. Limitations include:

• Incomplete Lifestyle Data: Lack of granular detail on socioeconomic status, smoking, or alcohol use in some datasets.

• Birth Weight Variations: Limited information regarding how birth weight might interact with neurodevelopmental outcomes.

• Symptom Severity: Difficulty in perfectly measuring the exact “severity” of a mother’s depression through records alone.

Practical Guidance for Expectant Mothers

For the approximately 5% of pregnant women in the United States currently prescribed antidepressants, this study suggests a shift toward more confident management of mental health.

For women with mild symptoms, non-pharmacological approaches like Cognitive Behavioral Therapy (CBT) remain a first-line option. However, for those with moderate to severe depression, the consensus among major medical bodies, including the CDC and SMFM, is that the benefits of maintaining medication typically outweigh the theoretical risks.

Bottom Line

The narrative surrounding antidepressants in pregnancy is shifting from one of caution and fear to one of evidence-based management. By demonstrating that the link to autism and ADHD is likely genetic rather than pharmacological, this research allows expectant mothers to prioritize their mental well-being without the weight of unfounded guilt.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/no-clear-autism-link-antidepressant-use-during-pregnancy-large-study-finds-2026-05-14/